Implanting a baroreceptor stimulation device for resistant hypertension

The Committee reviewed the evidence separately for bilateral and unilateral implantation. It noted that much of the available evidence was on bilateral implantation, but that unilateral stimulation was often used. It noted that the technology has evolved and unilateral implantation and stimulation is now used.

The Committee noted that non-adherence to medication is an important factor to consider in trials of resistant hypertension.

The Committee was aware of the difficulties in treating patients with drug resistant hypertension and the serious risks these patients face from uncontrolled high blood pressure.